Web Only Data Supplemental Figures Supplemental Figure 1 ...€¦ · decreases at week 12....
Transcript of Web Only Data Supplemental Figures Supplemental Figure 1 ...€¦ · decreases at week 12....
![Page 1: Web Only Data Supplemental Figures Supplemental Figure 1 ...€¦ · decreases at week 12. Biomarkers displaying significant, dose-dependent decreases (FDR](https://reader036.fdocuments.us/reader036/viewer/2022071008/5fc6771346de21763378f2d9/html5/thumbnails/1.jpg)
Web Only Data
Supplemental Figures
Supplemental Figure 1. Constituent biomarkers of the MBDA score exhibit dose-dependent
decreases at week 12. Biomarkers displaying significant, dose-dependent decreases (FDR<0.05)
include CRP (A), IL-6 (B), MMP-3 (C), SAA (D) and YKL-40 (E). All biomarkers were quantified using a
multiplex immunoassay system (Meso Scale Discovery MULTI-ARRAY Platform). Values are expressed
as the mean change in log10-transformed concentration between baseline and Week 12 by dose group.
Statistically significant differences for individual dose groups relative to placebo were determined using
the Wilcoxon rank-sum test.
![Page 2: Web Only Data Supplemental Figures Supplemental Figure 1 ...€¦ · decreases at week 12. Biomarkers displaying significant, dose-dependent decreases (FDR](https://reader036.fdocuments.us/reader036/viewer/2022071008/5fc6771346de21763378f2d9/html5/thumbnails/2.jpg)
(A) Change in CRP (log10 concentration)
(B) Change in IL-6 (log10 concentration)
![Page 3: Web Only Data Supplemental Figures Supplemental Figure 1 ...€¦ · decreases at week 12. Biomarkers displaying significant, dose-dependent decreases (FDR](https://reader036.fdocuments.us/reader036/viewer/2022071008/5fc6771346de21763378f2d9/html5/thumbnails/3.jpg)
(C) Change in MMP-3 (log10 concentration)
(D) Change in SAA (log10 concentration)
![Page 4: Web Only Data Supplemental Figures Supplemental Figure 1 ...€¦ · decreases at week 12. Biomarkers displaying significant, dose-dependent decreases (FDR](https://reader036.fdocuments.us/reader036/viewer/2022071008/5fc6771346de21763378f2d9/html5/thumbnails/4.jpg)
(E) Change in YKL-40 (log10 concentration
![Page 5: Web Only Data Supplemental Figures Supplemental Figure 1 ...€¦ · decreases at week 12. Biomarkers displaying significant, dose-dependent decreases (FDR](https://reader036.fdocuments.us/reader036/viewer/2022071008/5fc6771346de21763378f2d9/html5/thumbnails/5.jpg)
Supplemental Figure 2. CRP: Adjusted geometric mean ratio (mavrilimumab/placebo) with
upper/lower 95% CI
![Page 6: Web Only Data Supplemental Figures Supplemental Figure 1 ...€¦ · decreases at week 12. Biomarkers displaying significant, dose-dependent decreases (FDR](https://reader036.fdocuments.us/reader036/viewer/2022071008/5fc6771346de21763378f2d9/html5/thumbnails/6.jpg)
Supplemental Figure 3. ESR: Adjusted geometric mean ratio (mavrilimumab/placebo) with upper/lower 95% CI
![Page 7: Web Only Data Supplemental Figures Supplemental Figure 1 ...€¦ · decreases at week 12. Biomarkers displaying significant, dose-dependent decreases (FDR](https://reader036.fdocuments.us/reader036/viewer/2022071008/5fc6771346de21763378f2d9/html5/thumbnails/7.jpg)
Supplemental Figure 4. Swollen joint count: Adjusted mean change from baseline in swollen joint
counts ±SEM
![Page 8: Web Only Data Supplemental Figures Supplemental Figure 1 ...€¦ · decreases at week 12. Biomarkers displaying significant, dose-dependent decreases (FDR](https://reader036.fdocuments.us/reader036/viewer/2022071008/5fc6771346de21763378f2d9/html5/thumbnails/8.jpg)
Supplemental Figure 5. Tender joint count: Adjusted mean change from baseline in swollen joint
counts ±SEM
![Page 9: Web Only Data Supplemental Figures Supplemental Figure 1 ...€¦ · decreases at week 12. Biomarkers displaying significant, dose-dependent decreases (FDR](https://reader036.fdocuments.us/reader036/viewer/2022071008/5fc6771346de21763378f2d9/html5/thumbnails/9.jpg)
Supplemental Figure 6. Lung injury biomarkers: Box plots by time (A) Surfactant protein D; (B) KL-6
(A) Surfactant protein D
(B) KL-6
![Page 10: Web Only Data Supplemental Figures Supplemental Figure 1 ...€¦ · decreases at week 12. Biomarkers displaying significant, dose-dependent decreases (FDR](https://reader036.fdocuments.us/reader036/viewer/2022071008/5fc6771346de21763378f2d9/html5/thumbnails/10.jpg)
Investigators
The authors would like to thank the following EARTH study investigators for their valuable contribution to
the study: Bulgaria: Anastas Batalov, Ivan Goranov, Vladimir Kadinov, Rumen Stoilov, Daniela Yaneva;
Czech Republic: Jiri Vencovsky, Ladislav Bortlik, Petr Vitek, Dagmar Galatikova, Zuzana Urbanova,
Zuzana Stejfova; Estonia: Eevi Parsik, Jaak Talli, Ivo Valter; Hungary: Ildiko Kiss, Janos Bartalos, Istvan
Szombati, Marianne Szongoth; Latvia: Helena Mikazane, Samite Saleniece, Daina Saulite-Kandevica;
Lithuania: Sigitas Stonkus, Algirdas Venalis; Poland: Dariusz Chudzik, Stefan Daniluk, Przemyslaw
Kotyla, Iwona Swierzewska-Olech, Leszek Szczepanski, Malgorzata Szymanska, Piotr Leszczynski,
Wlodzimierz Samborski, Maria Stopinska- Polaszewska, Grazyna Krzyzanowska; Romania: Florin
Radulescu, Marian Sandu; Russia: Olga Ershova, Anna Galustyan, Alexander Gordienko, Nikolay
Korshunov, Galina Matsievskaia, Ildar Salikhov, Valeriy Shirinskiy, Elena Zonova, Olga Barbarash, Galina
Chumakova, Andrey Dorokhov; Ukraine: Kateryna Amosova, Oleksandr Dyadyk, Mykola Vatutin,
Volodymyr Kovalenko, Vladislav Povoroznyuk, Semen Ter-Vartanyan, Grigoriy Ignatenko